Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 11/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | FLT4 | P35916 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576442 | 0.94 | PTK2 (0.45) | PTK2JAK3FLT4KDR | |
| SCHEMBL14576867 | 0.94 | PTK2 (0.46) | PTK2JAK3FLT4KDR | |
| SCHEMBL15524884 | 0.93 | PTK2 (0.43) | PTK2FLT4KDR | |
| SCHEMBL12479394 | 0.93 | PTK2 (0.48) | PTK2JAK3FLT4KDR | |
| SCHEMBL15524110 | 0.93 | PTK2 (0.46) | PTK2FLT4KDR | |
| SCHEMBL12478666 | 0.88 | PTK2 (0.47) | PTK2FLT4KDR | |
| SCHEMBL12478847 | 0.88 | PTK2 (0.48) | PTK2JAK3FLT4KDR | |
| SCHEMBL14576729 | 0.87 | PTK2 (0.49) | PTK2JAK3FLT4KDR | |
| SCHEMBL12478821 | 0.87 | CCND3 (0.52) | PTK2EGFRJAK3MAPT | |
| SCHEMBL15524715 | 0.87 | CCNA2 (0.51) | PTK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 240/4885EGFR 30/4885ERBB2 24/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 260/4885EGFR 14/4885ERBB2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.